image
Healthcare - Drug Manufacturers - General - NASDAQ - US
$ 88.4
-4.03 %
$ 110 B
Market Cap
982.22
P/E
1. INTRINSIC VALUE

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.[ Read More ]

The intrinsic value of one GILD stock under the base case scenario is HIDDEN Compared to the current market price of 88.4 USD, Gilead Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GILD

image
FINANCIALS
27.1 B REVENUE
-0.60%
7.6 B OPERATING INCOME
3.75%
5.61 B NET INCOME
22.93%
8.01 B OPERATING CASH FLOW
-11.75%
-2.26 B INVESTING CASH FLOW
8.15%
-5.12 B FINANCING CASH FLOW
20.78%
7.54 B REVENUE
8.58%
888 M OPERATING INCOME
-66.96%
2.56 B NET INCOME
58.36%
4.31 B OPERATING CASH FLOW
225.21%
-710 M INVESTING CASH FLOW
-131.27%
-1.38 B FINANCING CASH FLOW
53.30%
Balance Sheet Decomposition Gilead Sciences, Inc.
image
Current Assets 16.1 B
Cash & Short-Term Investments 7.26 B
Receivables 4.66 B
Other Current Assets 4.16 B
Non-Current Assets 46 B
Long-Term Investments 1.16 B
PP&E 5.32 B
Other Non-Current Assets 39.6 B
Current Liabilities 11.3 B
Accounts Payable 550 M
Short-Term Debt 1.8 B
Other Current Liabilities 8.93 B
Non-Current Liabilities 28.1 B
Long-Term Debt 23.2 B
Other Non-Current Liabilities 4.91 B
EFFICIENCY
Earnings Waterfall Gilead Sciences, Inc.
image
Revenue 27.1 B
Cost Of Revenue 5.97 B
Gross Profit 21.1 B
Operating Expenses 13 B
Operating Income 7.6 B
Other Expenses 1.99 B
Net Income 5.61 B
RATIOS
77.99% GROSS MARGIN
77.99%
28.05% OPERATING MARGIN
28.05%
20.89% NET MARGIN
20.89%
24.81% ROE
24.81%
9.12% ROA
9.12%
13.01% ROIC
13.01%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Gilead Sciences, Inc.
image
Net Income 5.61 B
Depreciation & Amortization 2.69 B
Capital Expenditures -585 M
Stock-Based Compensation 795 M
Change in Working Capital -2.3 B
Others 899 M
Free Cash Flow 7.42 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Gilead Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for GILD of $84.5 , with forecasts ranging from a low of $69 to a high of $105 .
GILD Lowest Price Target Wall Street Target
69 USD -21.95%
GILD Average Price Target Wall Street Target
84.5 USD -4.38%
GILD Highest Price Target Wall Street Target
105 USD 18.78%
4. DIVIDEND ANALYSIS
1.88% DIVIDEND YIELD
0.77 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Gilead Sciences, Inc.
image
Sold
0-3 MONTHS
7.96 M USD 2
3-6 MONTHS
543 K USD 2
6-9 MONTHS
891 K USD 1
9-12 MONTHS
1.13 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 week ago
Nov 06, 2024
Sell 456 K USD
Mercier Johanna
Chief Commercial Officer
- 5000
91.28 USD
1 week ago
Nov 06, 2024
Sell 1.88 M USD
Parsey Merdad
Chief Medical Officer
- 20590
91.5 USD
1 week ago
Nov 06, 2024
Sell 458 K USD
Parsey Merdad
Chief Medical Officer
- 5000
91.5 USD
1 month ago
Oct 01, 2024
Sell 168 K USD
Parsey Merdad
Chief Medical Officer
- 2000
83.83 USD
2 months ago
Sep 12, 2024
Sell 1.8 M USD
Parsey Merdad
Chief Medical Officer
- 21246
84.5 USD
2 months ago
Sep 12, 2024
Sell 1.34 M USD
Mercier Johanna
Chief Commercial Officer
- 15925
84.23 USD
2 months ago
Sep 12, 2024
Sell 1.12 M USD
Mercier Johanna
Chief Commercial Officer
- 13432
83.25 USD
2 months ago
Aug 28, 2024
Sell 742 K USD
Mercier Johanna
Chief Commercial Officer
- 9513
78.03 USD
3 months ago
Aug 13, 2024
Sell 406 K USD
Mercier Johanna
Chief Commercial Officer
- 5490
73.98 USD
4 months ago
Jul 01, 2024
Sell 137 K USD
Parsey Merdad
Chief Medical Officer
- 2000
68.63 USD
7 months ago
Apr 01, 2024
Sell 146 K USD
Parsey Merdad
Chief Medical Officer
- 2000
72.96 USD
8 months ago
Feb 28, 2024
Sell 146 K USD
Parsey Merdad
Chief Medical Officer
- 2000
73.18 USD
8 months ago
Feb 29, 2024
Sell 599 K USD
Parsey Merdad
Chief Medical Officer
- 8230
72.7368 USD
10 months ago
Jan 16, 2024
Sell 429 K USD
Dickinson Andrew D
Chief Financial Officer
- 5000
85.78 USD
10 months ago
Jan 09, 2024
Sell 702 K USD
Mercier Johanna
Chief Commercial Officer
- 8242
85.23 USD
1 year ago
Oct 17, 2023
Sell 400 K USD
Dickinson Andrew D
Chief Financial Officer
- 5000
80.0034 USD
1 year ago
Sep 12, 2023
Sell 116 K USD
Parsey Merdad
Chief Medical Officer
- 1501
76.99 USD
1 year ago
Jul 20, 2023
Sell 400 K USD
Dickinson Andrew D
Chief Financial Officer
- 5000
80 USD
1 year ago
Jun 13, 2023
Sell 114 K USD
Parsey Merdad
Chief Medical Officer
- 1485
76.9 USD
1 year ago
Mar 13, 2023
Sell 484 K USD
Parsey Merdad
Chief Medical Officer
- 6126
78.99 USD
1 year ago
Mar 01, 2023
Sell 1.04 M USD
Parsey Merdad
Chief Medical Officer
- 12984
79.9619 USD
1 year ago
Dec 30, 2022
Sell 47.2 K USD
Parsey Merdad
Chief Medical Officer
- 553
85.33 USD
2 years ago
Nov 09, 2022
Sell 536 K USD
Wilfong Diane E.
SVP, Controller & CAO
- 6416
83.5 USD
2 years ago
Nov 01, 2022
Sell 1.29 M USD
Wilfong Diane E.
SVP, Controller & CAO
- 16255
79.25 USD
2 years ago
Mar 10, 2022
Sell 212 K USD
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel
- 3634
58.24 USD
2 years ago
Feb 09, 2022
Sell 108 K USD
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel
- 1691
63.89 USD
2 years ago
Feb 01, 2022
Sell 964 K USD
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel
- 14061
68.5358 USD
3 years ago
Aug 17, 2021
Sell 987 K USD
Wilfong Diane E.
SVP, Controller & CAO
- 13610
72.5 USD
3 years ago
May 04, 2021
Sell 1.29 M USD
Mercier Johanna
Chief Commercial Officer
- 19496
66.0929 USD
3 years ago
May 03, 2021
Sell 1.31 M USD
Whitley Richard James
Director
- 20282
64.5723 USD
3 years ago
Mar 11, 2021
Sell 94.2 K USD
Pletcher Brett A
EVP,Corp Affairs & Gen Counsel
- 1486
63.36 USD
7. News
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease On Friday, Gilead Sciences, Inc.  GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi. benzinga.com - 1 day ago
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study, which showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi® (seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression. Additionally, 41% (15 out of 37) of participants achieved normaliz. businesswire.com - 1 day ago
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? zacks.com - 2 days ago
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com - 2 days ago
Gilead Sciences to close Seattle office; shutdown impacts 72 employees Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday. geekwire.com - 3 days ago
Gilead Prices $3.5 Billion of Senior Unsecured Notes FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturin. businesswire.com - 3 days ago
Gilead initiated with a Buy at Citi Citi initiated coverage of Gilead with a Buy rating and $125 price target. The firm says that despite the stock's near-term outperformance, it remains bullish based primarily on upside from Biktarvy led near-term HIV growth and lenacapavir driven long-term growth. It sees "upside growth" in Gilead's combined HIV franchise and believes lenacapavir "could boost" its next phase of growth. https://thefly.com - 3 days ago
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lenac. businesswire.com - 4 days ago
GILD or VRTX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 4 days ago
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed agents with varied dosing frequencies and administration methods. The key findings presented at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024) reflect a transformative portfolio and future-looking pipeline focused on. businesswire.com - 5 days ago
3 Spectacular High-Yield Dividend Stocks to Buy in November High yields aren't a warning indicator with these three stocks. fool.com - 1 week ago
Gilead Sciences: Finally Some Real Momentum Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance on its HIV franchise remains high, with recent positive pipeline news and better-than-expected performance driving shares up 50% since summer. Despite reasonable valuations at 13 times adjusted earnings, I'm cautious due to slower oncology growth and the momentum already displayed by the stock. seekingalpha.com - 1 week ago
8. Profile Summary

Gilead Sciences, Inc. GILD

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 110 B
Dividend Yield 1.88%
Description Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Contact 333 Lakeside Drive, Foster City, CA, 94404 https://www.gilead.com
IPO Date Jan. 22, 1992
Employees 18000
Officers Dr. Flavius Martin M.D. Executive Vice President of Research Dr. Linda Slanec Higgins Ph.D. Senior Vice President of Research, Innovation & Portfolio Ms. Sandra Patterson Senior Vice President, Corporate Controller & Principal Accounting Officer Ms. Jyoti K. Mehra Executive Vice President of Human Resources Dr. Rudolf Ertl Senior Vice President of Commercial Operations of Australia, Canada, Europe Mr. Daniel P. O'Day Chairman & Chief Executive Officer Dr. Merdad V. Parsey M.D., Ph.D. Chief Medical Officer Ms. Johanna Mercier Chief Commercial Officer Ms. Jacquie Ross C.F.A. Vice President of Investor Relations Mr. Andrew D. Dickinson Chief Financial Officer